Bioventus Stock Analysis
BVS Stock | USD 11.51 0.10 0.88% |
Bioventus is overvalued with Real Value of 8.02 and Target Price of 4.5. The main objective of Bioventus stock analysis is to determine its intrinsic value, which is an estimate of what Bioventus is worth, separate from its market price. There are two main types of Bioventus' stock analysis: fundamental analysis and technical analysis.
The Bioventus stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Bioventus is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. Bioventus Stock trading window is adjusted to America/New York timezone.
Bioventus |
Bioventus Stock Analysis Notes
About 70.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 2.14. Bioventus recorded a loss per share of 0.61. The entity had not issued any dividends in recent years. Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the bodys natural healing process in the United States and internationally. The company was founded in 2011 and is headquartered in Durham, North Carolina. Bioventus Inc operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 1160 people. For more info on Bioventus please contact Kenneth Reali at 919 474 6700 or go to https://www.bioventus.com.Bioventus Quarterly Total Revenue |
|
Bioventus Investment Alerts
Bioventus had very high historical volatility over the last 90 days | |
Bioventus has high likelihood to experience some financial distress in the next 2 years | |
Bioventus has 394.85 M in debt with debt to equity (D/E) ratio of 1.17, which is OK given its current industry classification. Bioventus has a current ratio of 0.92, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Note however, debt could still be an excellent tool for Bioventus to invest in growth at high rates of return. | |
The entity reported the last year's revenue of 512.35 M. Reported Net Loss for the year was (96.74 M) with profit before taxes, overhead, and interest of 302.71 M. | |
About 70.0% of Bioventus shares are held by institutions such as insurance companies | |
Latest headline from finance.yahoo.com: German toy and games sector hopes for seasonal upswing amid slowdown |
Bioventus Upcoming and Recent Events
29th of March 2024 Upcoming Quarterly Report | View | |
21st of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
29th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Bioventus Largest EPS Surprises
Earnings surprises can significantly impact Bioventus' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2022-05-10 | 2022-03-31 | 0.05 | 0.04 | -0.01 | 20 | ||
2021-08-10 | 2021-06-30 | 0.14 | 0.16 | 0.02 | 14 | ||
2024-11-05 | 2024-09-30 | 0.03 | 0.06 | 0.03 | 100 |
Bioventus Environmental, Social, and Governance (ESG) Scores
Bioventus' ESG score is a quantitative measure that evaluates Bioventus' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Bioventus' operations that may have significant financial implications and affect Bioventus' stock price as well as guide investors towards more socially responsible investments.
Bioventus Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Ophir Asset Management Pty Ltd | 2024-09-30 | 524.2 K | State Street Corp | 2024-06-30 | 487.3 K | Charles Schwab Investment Management Inc | 2024-09-30 | 390.2 K | Renaissance Technologies Corp | 2024-09-30 | 387.9 K | Oberweis Asset Management Inc | 2024-06-30 | 380.9 K | Segall Bryant & Hamill | 2024-09-30 | 377.8 K | Pura Vida Investments, Llc | 2024-09-30 | 352.6 K | Marshall Wace Asset Management Ltd | 2024-06-30 | 332.3 K | Northern Trust Corp | 2024-09-30 | 322.4 K | Essex Woodlands Health Ventures | 2024-09-30 | 13 M | Nantahala Capital Management, Llc | 2024-06-30 | 10.7 M |
Bioventus Market Capitalization
The company currently falls under 'Small-Cap' category with a total capitalization of 745.85 M.Bioventus Profitablity
The company has Net Profit Margin of (0.07) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of 0.05 %, which entails that for every 100 dollars of revenue, it generated $0.05 of operating income.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.49) | (0.46) | |
Return On Capital Employed | (0.13) | (0.12) | |
Return On Assets | (0.19) | (0.18) | |
Return On Equity | (0.90) | (0.85) |
Management Efficiency
Bioventus has Return on Asset of 0.0248 % which means that on every $100 spent on assets, it made $0.0248 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2476) %, meaning that it generated no profit with money invested by stockholders. Bioventus' management efficiency ratios could be used to measure how well Bioventus manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.46 in 2024. Return On Capital Employed is likely to gain to -0.12 in 2024. At this time, Bioventus' Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 3.3 M in 2024, whereas Total Current Assets are likely to drop slightly above 212 M in 2024.Last Reported | Projected for Next Year | ||
Book Value Per Share | 3.53 | 3.24 | |
Tangible Book Value Per Share | (4.29) | (4.50) | |
Enterprise Value Over EBITDA | (29.82) | (28.33) | |
Price Book Value Ratio | 1.90 | 1.81 | |
Enterprise Value Multiple | (29.82) | (28.33) | |
Price Fair Value | 1.90 | 1.81 | |
Enterprise Value | 688 M | 1.2 B |
The leadership approach at Bioventus' fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Operating Margin 0.0478 | Profit Margin (0.07) | Beta 0.88 | Return On Assets 0.0248 | Return On Equity (0.25) |
Technical Drivers
As of the 22nd of November, Bioventus shows the Risk Adjusted Performance of 0.1193, downside deviation of 4.13, and Mean Deviation of 2.66. Bioventus technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Bioventus coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Bioventus is priced correctly, providing market reflects its regular price of 11.51 per share. Given that Bioventus has jensen alpha of 0.5486, we suggest you to validate Bioventus's prevailing market performance to make sure the company can sustain itself at a future point.Bioventus Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Bioventus middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Bioventus. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Bioventus Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bioventus insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bioventus' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bioventus insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bioventus Outstanding Bonds
Bioventus issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bioventus uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bioventus bonds can be classified according to their maturity, which is the date when Bioventus has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
Boeing Co 2196 Corp BondUS097023DG73 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
International Game Technology Corp BondUS460599AD57 | View | |
Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
AerCap Global Aviation Corp BondUS00773HAA59 | View |
Bioventus Predictive Daily Indicators
Bioventus intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Bioventus stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Accumulation Distribution | 10313.09 | |||
Daily Balance Of Power | 0.2439 | |||
Rate Of Daily Change | 1.01 | |||
Day Median Price | 11.38 | |||
Day Typical Price | 11.42 | |||
Price Action Indicator | 0.18 | |||
Period Momentum Indicator | 0.1 |
Bioventus Corporate Filings
14th of November 2024 Other Reports | ViewVerify | |
13A | 8th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 5th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
4th of November 2024 Other Reports | ViewVerify | |
25th of October 2024 Other Reports | ViewVerify | |
8K | 4th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 20th of August 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 6th of August 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Bioventus Forecast Models
Bioventus' time-series forecasting models are one of many Bioventus' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Bioventus' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Bioventus Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Bioventus prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Bioventus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Bioventus. By using and applying Bioventus Stock analysis, traders can create a robust methodology for identifying Bioventus entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (0.24) | (0.22) | |
Operating Profit Margin | (0.16) | (0.15) | |
Net Loss | (0.30) | (0.29) | |
Gross Profit Margin | 0.64 | 0.76 |
Current Bioventus Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Bioventus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Bioventus analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
4.5 | Buy | 3 | Odds |
Most Bioventus analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Bioventus stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Bioventus, talking to its executives and customers, or listening to Bioventus conference calls.
Bioventus Stock Analysis Indicators
Bioventus stock analysis indicators help investors evaluate how Bioventus stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Bioventus shares will generate the highest return on investment. By understating and applying Bioventus stock analysis, traders can identify Bioventus position entry and exit signals to maximize returns.
Begin Period Cash Flow | 31.8 M | |
Long Term Debt | 367 M | |
Common Stock Shares Outstanding | 62.6 M | |
Total Stockholder Equity | 173.6 M | |
Tax Provision | -16.3 M | |
Property Plant And Equipment Net | 50 M | |
Cash And Short Term Investments | 37 M | |
Cash | 37 M | |
Accounts Payable | 23 M | |
Net Debt | 357.9 M | |
50 Day M A | 12.0082 | |
Total Current Liabilities | 175.5 M | |
Other Operating Expenses | 594.1 M | |
Non Current Assets Total | 542.9 M | |
Forward Price Earnings | 16.0772 | |
Non Currrent Assets Other | 3.1 M | |
Stock Based Compensation | 2.7 M |
Additional Tools for Bioventus Stock Analysis
When running Bioventus' price analysis, check to measure Bioventus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioventus is operating at the current time. Most of Bioventus' value examination focuses on studying past and present price action to predict the probability of Bioventus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioventus' price. Additionally, you may evaluate how the addition of Bioventus to your portfolios can decrease your overall portfolio volatility.